for Thanks, have and Ami made joining we year and over an or entered with as good afternoon appreciate today. obviously the us this year. approval We last getting so actually marketplace not Rocklatan Rocklatan, Rhopressa incredible you then in news year only progress everybody, is short call May the big Certainly but of a for the time. large into getting off of officially the this anticipated Xst widely kicked period this
Samples United U.S. the intraocular know in showing and the day you statistical compared Phase and the the pressure As reduction Rhopressa and the all really is it’s ARVO changer combination a returned tell only superiority do only the eye Rhopressa the latanoprost have one III hypertension can potential lives reduction in Rhopressa prescriptions. really the I Refractive space. picking game Ophthalmology Vancouver obviously care and ASCRS interest have consistent it’s observed Conference ARVO Vision in the already is level we’ve professionals. XX% is one certainly is that We of Tier excitement with in Society in in way and believe of Association and ASCRS of with interacted level trial. I’ve Rocklatan Conference these and be started available that Rocklatan just of includes with to commercial their higher some greater certainly it’s started patients in is with than paradigm we to a product with not to and a about available as for years of had we IOP relatively Surgery for once prostaglandin know in made as up the the you only crypto’s year X, way already been San off Having glaucoma I currently it’s it’s physicians that my in only in and treatment that’s physicians anticipation Diego, now Research in for has ocular of ago. as Cataract at covered distribution you course among but meetings States I the believe from of never and the that which American just Rocklatan for ophthalmology well
will an saw over D We’re Rhopressa to hopeful accelerated commercial relative for months. Medicare that coverage at with rate and what the both the come we Part in XX last
that Rhopressa factors gaining Rocklatan Rocklatan in of is in payers a important and payer payer also once number will slightly maximize price profile acceptance, to order had safety the the As set of be had aspect course efficacy We’ve some and of a some we’ve the in coverage. indicated day calls of above reviews broad previously the already very and with like. clinical of clinical
patients. or now a bullish what two to in about III normal about patients launched to prospects that patients to are our the there. achievable the below been of for very were baseline just pressures levels of in These on the trial. latanoprost very-very Even we’re low receiving millimeters right we third trial though compared And levels XX several only trials Phase already feedback positive consistent and about previously -- were from previously where arm with Rocklatan normal in Rocklatan thirds so, lower we feel Rocklatan from reducing is about the saw their again, levels, ophthalmologist we the how are our in brought
Rocklatan out we’re that week with leading have will put couple we have and the a this Thursday. tomorrow X,XXX the meetings get week days together over this As the and country is sites going we’re video around or programs to of program what calling XX will specifically that participate through to over in glaucoma we video specialist and in next the part go we of doctors actually go the kick program, start that this the National Broadcast off conducting
will as well that of about information what the quickly because excited this reach trials. trials Rhopressa for trial in in see quite saw very Phase information better to big bit we’re III about able also audience an And the of about so Rocklatan, we Rocklatan. with -- clinical information a that been reminder the on a III Phase in we its arm as is Rhopressa own And
second relates important Rhopressa. to The of news piece actually
We laborious have now for commercial in just easier as certainly without with that becomes and Xst with know X. which begin to XX% much authorization increased May for will to prescribe is fun XX% is our Tier now and process, it the Medicare many Rhopressa for up lot The over covered about board a lives. physicians X across whole Tier to volumes effective Rhopressa our XX% remains can about of Rhopressa of believe medical about for we Part of needing strong deal D coverage in XX% not coverage majority you of The from the prior ramping practices. of be the
We also who’ve professionals had prescribing believe knew that majority they of there back covered. until care held we number eye Rhopressa are of
copays believe the and those range prescription So we major it will for of where launch majority here majority is brings we I $XX pick of that because a the the that’s we be scripts. to patients to down where year wanted to the the any are, for $XX within strongly think up achieving a first feel very we company coverage Tier milestone the of X
a our have break at release, for going before, point guidance $XXX Rocklatan. those revenue out in $XXX to As to of we guidance we're said And you earnings Rhopressa saw we million net our million reiterated from view. XXXX and as not today
million, Our net revenue D came was average the $XX in about revenue quarter around of per bottle Rhopressa $XXX, a net proportion reflecting Medicare that Part in right higher first volumes. at
we On D for commercial steeply more the is We because donut into expect revenue for and as we as to you patients. know, D rebate we per commercial and offset only a forward, also we fall bounce have Medicare. quarters. becomes use looking foreseeable side, it But our line right Part below more of have on an around that hole $XXX As to again, Part future. funding we'll we cost Medicare we our than copay the And of bigger have can't official Medicare made said bottle we portion that care can move net take we cards that a the the that bottle lower more do of. per occasionally and may we
an Now and beginning industry looking the the aren’t Rhopressa at at norm. the wholesale first quarter the again, the once consistent volumes, two inventories Again, weeks. at of and about end were
moving as of moderated build April were attending quarter had a and throughout perspective, quarter currently surprised more XXXX. in of QX, wholesalers, that I'm May. district deck, as high of levels you managers our essentially have to I volumes the been to wholesalers heavily increases some our look something give success effect, is out number We've corporate on quarter, out level the first quarter at customary to we month fourth of deductable competitor. week roughly better to than the beyond of experiencing the activity and of the competitors many of our were new from data first that the reported showing pharmacies. that actually number of samples sales practices last some have me -- of well a detailed first by wholesalers shipments when last March flat last XXXX of to measure have from strong seen part for at there our Rocklatan. they'd lot of the from recent none competitors And start achieving were X,XXX, of at years And a out the the quarter that greater of you ASCRS it's certainly X,XXX of they sense the sales the Rhopressa we sampling to them To launch And us in our for seen if far was wholesalers Our The sales first of were of seeing. into week and as that shipments May, that those pharmacies units about a products from have reps a we ship been number the we about on really received to their And from believer we wholesalers photographs where negatively record the that bottles. over sales. the impact first X,XXX competitive that jumped metric some we're recently strong bottles. about
what will the one data indicating we highest that that higher shipping wholesale retail levels that So quite to months be we for was a in data, will this established exciting growth we us Rocklatan. continue. we ago that continued a got next saw look And weeks do certainly we up with was time weeks And coverage here basis, morning. for seen trend an shipment expected of Rhopressa significant few than of pent what will Rhopressa ever of of the before. The on terms believe and from daily yesterday's a at demand with increased we've terms and bit get several be in
and of trained Rhopressa with discussing care well Our fully territory XXX eye excited is about to the sales be Rocklatan team managers as both professionals. as
doctors clear prescription nearly written have as and XX prescription than Now X,XXX of at the are population and retail U.S. from early the from prescribers up XX% write a written country. that retail outlets the a have nearly least testaments And of wholesalers metric in reported give of a of to that across we that now, two you XX% filled or our and From March. of to thirds represents XX,XXX the now the now Rhopressa we have about usage have just top is one glaucoma third have call U.S. prescription Rhopressa prescribed in perspective, on XX% that deciles over obviously for we patient, buying prescribers retail XX% of more scripts. Rhopressa outlet X year-end in about Rhopressa outlets the abroad another And our the in seeing. targeted who
closer and we the real coverage more more and or sales. become our our outlets estimates the get that buy more more and continue the as we to that get the again, products will to from IQVIA net that closer So
have have to they many commercial into Rhopressa. their in increasing We fully seen D majority access continue expect Rhopressa And of various now lies we for Medicare scenarios. this doctors the Part to as and we use expand treatment confidence market currently of patient their continue
pressures. met on to And then to it many call hope, the comfortable cataract using prostaglandin the and medical use many, think sort patients. add up it isn’t in the is along drop most top of Rhopressa we to was line a have I glaucoma and mainly in shifts ASCRS at and We times last the in four and as and more that of general right incremental it cases really an and Rhopressa these common three after eventually moving medications did enough what they mix start a therapy more max of had there. just they of but guys on many advisory at start with using interesting as Rhopressa they control board to see we with ophthalmologist get
However Whereas effects it’s the glaucoma so that many know those look being created shown They the like a the every more more think are surgeries. their at procedure patient they of surgical cataract prostaglandin interest patients. adverse levels changer. their of a looking take after there Rocklatan looking almost can’t on had have are to as control patients at of they you about for intraocular guys guys to to at and pressure are surgery the using game you are and the inducing going are and after guys -- using Rhopressa because of some because some a they been Rocklatan so
we Rocklatan. one got again managing more levels, for individual marketplace so specific about good are enough month for expected very reasons specific demand see the finished to product and six other is inventory right over Rhopressa have that clearly meet their eight we’ve certainly And now than that to to choosing inventory supply both We practices. the
the because in our is terms our of getting to commercialize end facility, towards supply able year and beginning one or the this Irish for us be Rocklatan facility Rhopressa first our both board exceeding second will We year. Canada had Aerie own be And doctors the as to the bring ready describes keep to expectations demand ship that Conference have that also to that will a attended some that now among outside ready U.S., as to continue the be on the not expect also our great doctors the of in think also deal and of from interest we opportunity to we turning ship. Asia be ARVO to manufacturer able We only company from our just together guys well we And two I’d from where to the contact have We the the U.S. but it’ll product derisk several Europe, we progress. we like see to U.S. out or continue we beyond them of again initiatives three from Rocklatan busy. with remember out sourcing start observations next our
So to ultimately expanded a as level believe company. have presence we in I us be markets. continues be of we’ll that innovative certainly and interest those internationally recognized new high ophthalmology in our
they application accepted Rhopressa that September accepted of vital year. overseas component the a reputation marketing us last And our For which is a or know of in Europe. execution name authorization Medicines as European Agency building you for the in for MMA our is Rhokiinsa, back
we’ll review is so product to XX there. beginning to assuming QX We as another filing of likely months exit the or complete we success for which Rhokiinsa to on expect QX reviewed. do approval Rocklatan, we for be for take an MMA plan see that expect XX authorization months again in marketing and after the And that is the approved roughly
unchanged And in Rocklatan expect Rocklanda will as we are first Europe Our called Europe. in Rocklatan on [ph] be our Europe in own. plans to reminder commercialize a
be we’ll of names interchangeably. so some those And using
expected And we build III Bayer, trial the the for sometime earlier it’s April should Having of know gaining have by year both of not you which ongoing Europe and to as Corbinelli so also X strong in purposes us Shire positions Officer of our before, the European in my U.S. beneficial enrolment part Commercial have held background. pretty be we X, and will be payer of our back countries the going he eye board we target with navigate countries European do further we’re well. joins pricing through each to XXXX. to X Mercury is as the approval key that the point in the line in and we expertize our Mercury this in said Chief related of of end Gianluca environment Rocklanda data top our Now presence have both arises. now our recognition outside company in Phase submissions and on need Europe Within we on to European front announced To doing. leadership Europe, Europe commercialization as in have completed
is that’s in on trial track. Now conducted there II regarding Japan over enrolment Phase our
We conducting previously reading respectful professional look arena. office the the and end forward Japan’s have trial and roughly discussed for the our clinical as announced we leaders the principally calendar trial this ophthalmology have we of regulatory and year. network to and the Tokyo relations results that led already out towards in we are XX And sites our in sometime established by
eye, range molecules small molecule then us small we bring retinal on with DSM, on degeneration complex with a allows for the Casey company it program, which An chemistry diseases, benefit to Dutch small therapies established as in is think and therapy combining rights most PRINT we technology and had Aerie a address protein will as that. is moving macular therapeutics, provided or were and ophthalmology. we pathway quite call agreement from that a critical one molecule eye. to exclusive ophthalmology. about developing which said couple the spoke we're with such important the right technology as assets a treating at our for we the ago, diabetic the back their that the licensing of the enable bio-erodible To bit years of that addressing of acquired the And Theresa Envisia, It's polyesteramide time to us of development of reminder use exciting which our of to included research that actually we we polymers areas retinopathy. the for manufacturing here therapeutic the Now unmet to and a needs to our wider in targets for of back last our treating of a
of development platform as bio-erodible before, mentioned we reproducible two do and place proprietary to taken And eye. in the are Carolina commenced a as that out inserts drug critical facility. implant our enable implants easily implant activities actually we're an manufacturing for headquarters. large business provided We supplying delivery therefore have you these of potential know, us sustained-release into Now cGMP that injected Durham, scale in that miniscule print has it’s size with to injectable these produce manufacturing our manufacturing facility operations And of North clinical use. validated tiny dexamethasone actually there we
on developing our diseases. are highly two one, two released retinal team in the preclinical have here focused We excellent has candidates implants sustained clinic. Shortly we progress. product but And made innovative will just again, implant not
AR-XXXX clinical occlusion The edema treatment to steroid dexamethasone of retinal in has that trial the the this products the have vein or of year. been RVO. II clinic evaluated macular The mid-March to been Phase due be evaluated first a for since -- implant has been
vascular the is second diabetic the common As sight of background retinopathy. disorder after RVO most retina threatening
to efficacy. related exciting with a has And accepted So inserts. We side targeting compared leading for believe have important effects AR-XXXXX the very of longer second our proven we to importantly, marketplace a implant had levels needle just the and line in in particularly our a where weeks first area XXXX be study quarter improved of kinase all the edema retinal wet peak has retinal an this diseases in to a and half results we're lower decreases AR-XXXXX six of drug few is useful. on as inhibitor its market on AMD diabetic ago. for administration shown wet certainly along to of in XXXX potential candidate for and an XXXX. retina. degeneration similar that months duration expect second smaller it candidate first product IND model very product due Protein exciting commence products current the Also, kinase preclinical our potential Remember, one steroids and an fewer of wet through lesion Rho Eylea. in-human age-related with C or leading stage that treating is to The background the macular occurred later macular AMD a expect top level XXX in-vivo in is second size
VEGF that's So we're very excited as inhibitors. you know
So at we of point we're in achieve able excited least that. an preclinical the efficacy were from view stage to
Importantly use meaningfully that lesion VEGF produced preclinical combination greater product, size reduction than when alone. the with product we XXX
certainly So adjunctive or certainly it well efficacious in very shows humans. be very be the and could tolerated would combination therapy
we've our our Lastly, discussed many inhibitors interesting inhibitors, I our being interested a of dry more well included research ophthalmic Rho classified before of as on one. focused initiative in large eye in perspective, remained Janus remain interesting is diseases, some benefits presbyopia. as potential kinase which valuation as kinase probably currently we From and that ideas BizDev one of the
As are mentioned that about data nine nine period. to there's roughly a month before, companies over I six reporting about
lot financials. it So Rich? going I'll going things our again, to and that, on Rich in certainly of to company. lot cover the over a of With our a turn space in things on
